The pan-HDAC inhibitor Quisinostat has been shown to effectively reduce UM cell viability in vitro [29,37], and is currently being tested in clinical studies of advanced solid tumours and leukaemia [38]. This evidence concerns the gene HDAC9 and leukemia.